Swedish Orphan Biovitrum AB: Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion.
Te Pātaka Whaioranga – Pharmac has confirmed it is widening access to emicizumab (branded as Hemlibra) for the treatment of people with severe haemophilia A without factor VIII inhibitors. “Widening access to this treatment will help people manage .
Ascension Healthcare to Present Positive Phase 2 Data on Two Haemophilia Programmes at the 64th American Society of Hematology Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
LACHEN, Switzerland, Feb. 22, 2021 /PRNewswire/ Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq
® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal
Thrombosis and Haemostasis (Liesner RJ et al. Simoctocog Alfa (Nuwiq
®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623).
The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq